Does Bimzelx Treat Hidradenitis Suppurativa?
Bimzelx (bimekizumab-bkzx) is FDA-approved for treating moderate to severe hidradenitis suppurativa (HS) in adults whose condition has not improved with other systemic therapies.[1] It targets both IL-17A and IL-17F cytokines, which drive inflammation in HS, a chronic skin disease causing painful nodules, abscesses, and scarring in areas like armpits and groin.
Approval came in 2024 based on two Phase 3 trials (BE HEARD I and II), where 45-53% of patients achieved at least a 50% reduction in abscess and inflammatory nodule count (HiSCR50) at week 16, compared to 29% on placebo.[1][2] Long-term data showed sustained responses, with over 80% maintaining HiSCR50 at week 52 in responders.[2]
How Effective Is Bimzelx for HS Compared to Other Treatments?
In trials, Bimzelx outperformed placebo across endpoints like HiSCR75 (complete response in 30-35% of patients) and pain reduction (measured by HS Pain NRS).[2] It compares favorably to Humira (adalimumab, the only other biologic approved for HS), which has HiSCR50 rates of 46-52% at week 12 in its pivotal trial—Bimzelx showed similar or better results at week 16 with dual IL-17 blockade.[3]
Real-world use is limited due to recent approval, but early reports note faster flare reduction than TNF inhibitors for some patients.
What Dosage and Timeline for Results in HS?
Adults start with 320 mg (two 160 mg injections) every 4 weeks for the first three doses, then every 8 weeks.[1] Visible improvements often start by week 4-12, with peak efficacy around week 16; full scarring benefits may take longer.
Common Side Effects and Risks for HS Patients
Upper respiratory infections (14-20%), oral candidiasis (10-16%), and folliculitis (7-10%) are most frequent.[1] Serious risks include infections (monitor for tuberculosis), inflammatory bowel disease flares, and hypersensitivity. HS patients with active infections or immunosuppression should avoid it. No HS-specific black box warnings, unlike some biologics.
Who Makes Bimzelx and When Do Patents Expire?
UCB Pharma manufactures Bimzelx. Key U.S. patents expire in 2038-2041, per DrugPatentWatch.com, leaving room for biosimilars post-exclusivity but facing litigation risks.[4] No generics yet.
Alternatives if Bimzelx Isn't Suitable
| Treatment | Approval Status for HS | Key Mechanism | HiSCR50 Rate (Week 12-16) |
|-----------|-------------------------|---------------|---------------------------|
| Humira (adalimumab) | FDA-approved (2015) | TNF-alpha blocker | 46-52%[3] |
| Cosentyx (secukinumab) | Not approved; off-label | IL-17A blocker | ~45% in trials[5] |
| Stelara (ustekinumab) | Off-label | IL-12/23 blocker | 30-40% limited data[5] |
| Surgical excision | For severe cases | Removes lesions | N/A; adjunctive[6] |
Consult a dermatologist for personalized options, as response varies by HS stage (Hurley I-III).
Sources
[1]: FDA Label for Bimzelx
[2]: NEJM: BE HEARD I/II Trials
[3]: FDA Label for Humira HS
[4]: DrugPatentWatch.com: Bimzelx Patents
[5]: JAAD: Secukinumab/Ustekinumab HS Data
[6]: AAD HS Guidelines